Regeneron Pharmaceuticals Inc (REGN)

Debt-to-capital ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	1,984,400	1,984,000	1,983,600	1,983,300	1,982,900	1,982,600	1,982,200	1,981,800	1,981,400	1,981,100	1,980,700	1,980,400	1,980,000	1,979,600	1,979,200	1,978,900	1,978,500	1,978,300	—	—
Total stockholders’ equity	US$ in thousands	29,353,600	29,325,900	28,205,800	26,991,100	25,973,100	24,904,400	24,017,900	23,495,200	22,664,000	21,438,800	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000
Debt-to-capital ratio		0.06	0.06	0.07	0.07	0.07	0.07	0.08	0.08	0.08	0.08	0.09	0.09	0.10	0.10	0.12	0.14	0.15	0.16	0.00	0.00

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $1,984,400K ÷ ($1,984,400K + $29,353,600K)
= 0.06

Regeneron Pharmaceuticals Inc's debt-to-capital ratio has experienced a steady decline over the past few years. From March 31, 2020, at 0.00, the ratio gradually increased to 0.16 by September 30, 2020, indicating a slight increase in debt relative to the total capital. However, since then, the ratio has consistently decreased, reaching 0.06 by December 31, 2024. This declining trend suggests that the company has been effectively managing its debt levels in relation to its capital structure, potentially reducing financial risk and improving overall financial health.